Physician profile
Eric Hammer
NPI 1194180976
$1,422.27
in general payments reported to CMS, 2019-2025
19 companies · $184 in 2025
The $184 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $232 · 2022: $203 · 2023: $491 · 2024: $312 · 2025: $184.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $987.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $987.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $502.58 | 2021-2025 | |
| Pfizer INC. | $139.76 | 2021-2024 | |
| Xeris Pharmaceuticals, INC. | $134.33 | 2022-2024 | Gvoke Hypopen |
| Merck Sharp & Dohme LLC | $98.96 | 2021-2025 | Capvaxive, Gardasil 9, Rotateq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $86.12 | 2021-2025 | Jardiance, Synjardy, Tradjenta |
| Lilly USA, LLC | $82.06 | 2021-2025 | Mounjaro |
| Astrazeneca Pharmaceuticals Lp | $81.76 | 2023-2025 | Breztri, Airsupra, Farxiga |
| Organon LLC | $46.08 | 2021-2023 | Nexplanon |
| Mylan Specialty L.P. | $39.84 | 2023 | Yupelri, Yupelri |
| Sunovion Pharmaceuticals INC. | $38.85 | 2021 | |
| Harmony Biosciences LLC | $35.24 | 2024 | |
| Novo Nordisk INC | $23.72 | 2021 | |
| Edwards Lifesciences Corporation | $18.96 | 2022 | |
| Ibsa Pharma INC. | $17.89 | 2023 | Tirosint, Licart |
| Supernus Pharmaceuticals, INC. | $17.74 | 2024 | Qelbree |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $16.58 | 2023 | Prolia, Evenity |
| Agile Therapeutics, INC. | $15.04 | 2024 | Twirla |
| Indivior INC. | $13.39 | 2023 | Sublocade |
| Idorsia Pharmaceuticals US INC | $13.37 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Hammer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.